Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and suppresses the activity of KRAS G12C mutant proteins, thereby inhibiting KRAS G12C-dependent signaling pathways. Glecirasib exhibits high selectivity, potent inhibition, and favorable safety, and is primarily used in studies of non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
Molecular Weight:
640.03
Purity:
99.70%
CAS Number:
[2657613-87-9]
Formula:
C31H26ClF4N7O2
Target:
Ras|||Kras
T78651
T78651
* VAT and and shipping costs not included. Errors and price changes excepted
